Navigation Links
Myeloma in Medical News

Multiple Myeloma Genome Unlocked

Discovery paves way for better therapies for some blood cancer patients, experts say WEDNESDAY, July 29 (HealthDay News) -- The sequencing of the first three multiple myeloma whole genomes has been completed by U.S. scientists, who said this success will lead to a better understanding ...

CancerCare Launches New Program to Help Multiple Myeloma Patients Cover Transportation Costs

NEW YORK, July 20 /PRNewswire/ -- Cancer Care announced today the launch of the "Door to Door" program for patients with multiple myeloma. Cancer Care 's program will provide individual grants of up to $600 annually to multiple myeloma patients for covering transportation cost...

New Report Just Published: World Multiple Myeloma Therapeutics Market Report

NEW YORK, July 7 /PRNewswire/ -- Reportlinker.com just added a new market research report to its catalogue. World Multiple Myeloma Therapeutics Market http://www.reportlinker.com/p0119496/World-Multiple-Myeloma-Therapeutics-Market.html?utm_source=PRNWire&utm_medium=PR&utm...

MMRF and the Broad Institute to perform whole genome sequencing of multiple myeloma samples

The Multiple Myeloma Research Foundation (MMRF) announced today a collaboration with the Broad Institute of MIT and Harvard to systematically uncover the molecular changes underlying multiple myeloma by whole genome sequencing of individual patient tumors. The MMRF will provide both patient sample...

Data on VELCADE(R) (Bortezomib) for Injection Based Therapies to be Presented at the International Myeloma Workshop

CAMBRIDGE, Mass., Feb. 23 /PRNewswire/ -- Millennium: The Takeda Oncology Company today announced that 100 data presentations on VELCADE research will be featured at the Fifth International Myeloma Workshop (IMW) in Washington, D.C., February 26 - March 1, 2009. The 13 oral and 87 poster presenta...

International Panel of Experts Gather for Roundtable Consensus Regarding Multiple Myeloma Related Disease

LOS ANGELES, Feb. 23 /PRNewswire-USNewswire/ -- On Wednesday, February 25, 2009, the Institute for Myeloma and Bone Cancer Research (IMBCR) will host a roundtable discussion bringing leading scientists in the field of cancer research together to discuss monoclonal gammopathy of undetermined signif...

More>>

Myeloma in Medical Technology

Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting

Carfilzomib Achieves 26 Percent Clinical Benefit Response Rate in Phase 2 Trial of Relapsed and Refractory Multiple Myeloma Patients - Proteolix Expands Trial ORLANDO, Fla. and SOUTH SAN FRANCISCO, Calif., June 1 /PRNewswire/ -- Proteolix, Inc. today presented results from the company's most ...

Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting

New subset analysis of bortezomib-relapsed patient population demonstrates 55% overall response rate and extended time to progression NEW YORK, Feb. 26 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX ) today announced updated clinical results from an ongoing Phase 1/2...

Prolonged Progression-Free Survival Demonstrated by VELCADE(R) (Bortezomib) for Injection Based Induction Regimens in Transplant-Eligible Previously Untreated Multiple Myeloma Patients

SAN FRANCISCO, Dec. 8 /PRNewswire/ -- Millennium: The Takeda Oncology Company today reported updated results from two large, multi-center, randomized Phase III clinical trials of VELCADE based combinations for the induction treatment of transplant-eligible patients with previously untreated multip...

Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients

SAN FRANCISCO, Dec. 7 /PRNewswire/ -- Millennium: The Takeda Oncology Company today reported the Phase I results from a randomized, multi-center, Company-sponsored Phase I/II study of VELCADE, dexamethasone, cyclophosphamide and lenalidomide (VcDCR) in patients with previously untreated multiple m...

New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients

- Patients in the VELCADE, melphalan and prednisone arm demonstrated a significant survival benefit as well as a 30 percent complete response - CAMBRIDGE, Mass., Aug. 27 /PRNewswire/ -- Millennium: The Takeda Oncology Company today announced the publication of results from the 682 patient, ...

Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency

-- Recommendation based on study results demonstrating survival advantage of 18.4 months when added to standard therapy -- First study to show survival advantage over European standard of care BOULDER, Colo., Jan. 24 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM ) ...

More>>

Myeloma in Medical Products

Multiple Myeloma Panel by FISH

Description: ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' client...
Company:ARUP Laboratories

Chromosome Analysis, Multiple Myeloma Panel by FISH

Description: ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories' client...
Company:ARUP Laboratories
Myeloma in Medical Definition

Hematopathology

... ( ALL , CLL , HCL ) • Lymphoma ( Hodgkin's disease , NHL ) • LPD • myeloma ( Multiple myeloma , Extramedullary plasmacytoma ) Myeloid : Myeloid leukemia ( AML , ...

Pathology

... ( ALL , CLL , HCL ) • Lymphoma ( Hodgkin's disease , NHL ) • LPD • myeloma ( Multiple myeloma , Extramedullary plasmacytoma ) Myeloid : Myeloid leukemia ( AML , ...
Myeloma in Medical Dictionary

Myeloma

Multiple myeloma , also known as MM, myeloma , plasma cell myeloma , or as Kahler's disease is a cancer of the white blood cells known as plasma cells, which produce antibodies. Provides an overview of myeloma and its causes, symptoms, treatment and follow-up. Fightin...

Multiple myeloma

Multiple myeloma is a cancer of plasma cells. These immune cells are formed in bone marrow, are numerous in lymphatics and produce antibodies. Myeloma is regarded as incurable, but remissions may be induced with steroids,... Learn more about multiple myeloma , a form of cancer ...

Myoma

...a - Definition of Myoma at Dictionary.com a free online dictionary with ... Link To myoma . Myeloma. Leading Program For The Treatment Of Multiple myeloma ... Myoma is any tumor that arises from muscle tissue but usually refers to a ... Home " Health " Conditions & Treatments " Gynecologi...

Myeloproliferative Disorders

... Myeloproliferative disorders , or MPD, are a group of hematologic (blood) ... Myeloproliferative Disorders (MPD) Advances in the Treatment in myeloma ... The recent discovery of a key gene mutation has launched a flurry of promising ... The three main myeloproliferative disorders are po...

Karyotyping

... Digital karyotyping . ... Digital karyotyping provides a broadly applicable means for systematic detection ... ... translocations in multiple myeloma with multicolor spectral karyotyping . ... Multicolor spectral karyotyping (SKY) was performed on bone marrow samples from ... Karyotyping ...

Hyperviscosity

...red for complications of hyperviscosity . ... Provides an overview of myeloma and its causes, symptoms, treatment and ... excess protein in the blo...on in IgG myeloma. ... ( Hyperviscosity syndrome due to aggregation of myeloma globulin molecules? ... Paraproteinemia: blood hyperviscosity and ...
Myeloma in Biological News

Diverse genetic abnormalities lead to NF-κB activation in multiple myeloma

Two new studies may lead to the development of more effective therapies for individuals with multiple myeloma (MM), a common and incurable blood cell cancer. The research, published by Cell Press in the August issue of the journal Cancer Cell, provides new insight into the molecular mechanisms tha...

Genome changes tracked during multiple myeloma initiation, progression and treatment

Scientists have made significant progress toward elucidating key genetic events associated with the development and progression of multiple myeloma (MM), an incurable malignancy that is the second most common cancer of the blood. The results, published in the April issue of Cancer Cell, provide new...

Compound from marine bacteria shows potential as multiple myeloma therapy

An anti-cancer compound derived from bacteria dwelling in ocean-bottom sediments appears in laboratory tests to be a potent killer of drug-resistant multiple myeloma cells, and potentially with less toxicity than current treatments, report Dana-Farber Cancer Institute researchers in the November is...

IMF Launches World’s First DNA Database for Myeloma Patients

A biologist at Washington University in St. Louis has shown that for some fish species, females prefer males with larger sexual organs, and actually choose them for mating. That does not exclude males with an average-sized sex organ, called a gonopodium. These fish out-compete the larger-endowed ma...

CWRU receives $5 million from Ohio Third Frontier Commission

...l as by having access to leading-edge clinical therapies at our region's clinical institutions." The use of stem cells has focused on leukemia and myeloma treatments with recent applications in cardiovascular disease. Current healthcare is limited to the use of drugs or devices to treat disease and injur...

Scientists identify key gene that protects against leukemia

...ntical engraftment. This finding may have important ramifications for patients undergoing bone marrow transplants, for leukemia, lymphoma, multiple myeloma and certain cancers. "Currently, patients undergoing bone marrow transplants may not be getting enough of the quiescent transplanted HSCs that are ...
Myeloma in Biological Technology

Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association

SOUTH SAN FRANCISCO, Calif., June 8 /PRNewswire/ -- Proteolix, Inc. today announced data from ongoing Phase 2 and Phase 1b clinical trials of carfilzomib for the treatment of multiple myeloma at the 14th Congress of the European Hematology Association (EHA) in Berlin, Germany. Carfilzomib is the ...

Senesco Presents Pre-Clinical Multiple Myeloma Data at the 12th Annual Meeting of the American Society of Gene Therapy

NEW BRUNSWICK, N.J., May 27 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Amex: SNT ) announced today that Richard Dondero, Vice President of Research and Development, will be presenting pre-clinical data from Senesco's multiple myeloma studies at...

International Guidelines for First-Line use of Freelite(TM) in Diagnosis and Management of Multiple Myeloma to be Published in "Leukemia"

BIRMINGHAM, England, January 28 /PRNewswire/ -- The Binding Site Limited ("The Binding Site" or the "Company"), a privately-owned specialist U.K. diagnostics company, today announces the publication of the first international guidelines recommending first-line use of Freelite(TM) in the diagno...

Proteolix Announces Positive Data From Two Ongoing Phase 2 Clinical Trials of Carfilzomib in Multiple Myeloma at the 50th Annual Meeting of the American Society of Hematology

SOUTH SAN FRANCISCO, Calif., Dec. 9 /PRNewswire/ -- Proteolix, Inc. today announced positive clinical data demonstrating that the company's lead product, carfilzomib, has single-agent activity and promotes durable responses in patients with relapsed and refractory multiple myeloma. Carfilzomib is...

Senesco's Preclinical Multiple Myeloma Data to be Presented at the 20th EORTC-NCI-AACR Symposium on 'Molecular Targets and Cancer Therapeutics'

NEW BRUNSWICK, N.J., Oct. 20 /PRNewswire-FirstCall/ -- Senesco Technologies, Inc. ("Senesco" or the "Company") (NYSE Alternext US: SNT) announced today that Catherine Taylor, one of the Company's funded researchers, will be presenting her findings related to Senesco's preclinical multiple myel...

Oncolytics Biotech Inc. Collaborators Present Reovirus Research for Multiple Myeloma at AACR Annual Meeting

CALGARY, April 15 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY) announced that an oral presentation by Dr. Chandini Thirukkumaran of the Tom Baker Cancer Centre, Calgary, entitled "Targeting Multiple Myeloma with Oncolytic Viral Therapy" was presented today at the A...
Myeloma in Biological Products

Mouse Anti-Mouse Natural Killer Cell Receptor-P1 Monoclonal Antibody, Unconjugated, Clone 1C10 from CHEMICON

Description:...doma produced by the fusion of splenocytes from BALB/c mice immunized (BALB/c X C57BL/6)F1 (CbyB6F1) lymphokine-activated killer (LAK) cells and mouse myeloma cellline. Available Date: 38245...
Company:CHEMICON

Mouse Anti-PRMT5 Monoclonal Antibody, Unconjugated, Clone PRMT5-21 from GeneTex

Description:...se antibodies can be utilized to explore arginine methylation and its regulatory functions. Immunogen: Antibody was produced by the fusion of mouse myeloma cells and splenocytes from mice immunized with PRMT5 containing the C-terminal region of the Human PRMT5 (amino acids 315-637)....
Company:GeneTex

Hybridoma Development from QED Bioscience Inc.

Description:...: 10-14 weeks ($1,845.00) PHASE II: FUSION 1. Spleen cells from selected animals are fused with two different myeloma cell lines. 2. Remaining fusion cocktail is frozen for future use, if necessary. Estimated completion time: 2-3 weeks ($3,690.00) PHA...
Company:QED Bioscience Inc.
Myeloma in Biological Definition

Antibody

... (1 and 2), beta-globulins (1 and 2) and gamma-globulins according to weight. Immunoglobulins are all in the gamma region. In some disease states ( myeloma ) a very high concentration of one particular immunoglobulin will show up as a monoclonal band. Isotypes According to differences in their ...

Cancer

...rcinoma , blood (and bone marrow ) - hematological malignancies , leukemia , lymphoma , Hodgkin's disease , non-Hodgkin's lymphoma , multiple myeloma , brain tumor , breast cancer , cervical cancer , colorectal cancer - in the colon , rectum , anus , or appendix , esophageal cancer , endo...

Monoclonal antibody

...th the antigen. These B-cells are then fused with myeloma tumor cells that can grow indefinitely in cultu...d called ascites fluid. In the above process, myeloma cell lines are used that have lost their ability t...te the target antibody. Furthermore, one uses only myeloma cells that have lost a specific enzyme ( hypoxan...
Myeloma in Biological Dictionary

Plasma cells

... the bone marrow leads to ... In addition, the abnormal plasma cells almost always produce a large amount of a ... Clinical Trials for Multiple myeloma / Plasma Cell Neoplasms at UPMC ... The plasma cells make a different antibody to fight each type of bacteria or ... Information about ...

Hybridoma

...s hybridoma mean? ... hybridoma /hy·brid·o·ma/ (hi′′brid-o'mah) a somatic cell hybrid formed by fusion ... fusion of B lymphocytes with myeloma cells to create hybridomas ... Through these initiatives, the Hybridoma Core will remain on the cutting edge of ... This tutorial illustrates...
Other Tags
(Date:7/13/2014)... (PRWEB) July 13, 2014 Athletes with ... recovery period from concussions, according to research presented today ... AOSSM ) Annual Meeting. The research marks the first ... based on the known physical events that occur after ... with a long allele in the (GT)n genotype were ...
(Date:7/13/2014)... July 13, 2014 Fadhits.com is popular ... prom dresses are extremely beautiful. Recently, the company has ... for 2014. What’s more, all these outfits are ... off). , Additionally, the supplier is now offering ... elegant Quinceanera dresses, it has many other designs for ...
(Date:7/13/2014)... Wright & Schulte LLC has learned ... in July of 2015, in U.S. District Court, District ... the discovery process in the South Carolina federal ... over the multidistrict litigation (MDL). The complaints pending in ... who allege that they took the statin medication to ...
(Date:7/13/2014)... MI (PRWEB) July 13, 2014 If Dr. ... program he has just launched at http://www.HealthYourself101.com will ... visceral obesity. , Power has set out to provide ... ill effects that’s actually – dare we say it? – ... program,” says Power, “aims to engage the remote learner – ...
(Date:7/12/2014)... a well-known wedding dress manufacturer and retailer, has added a ... its product line. In addition, the company has launched a ... more benefits for its loyal fans. All its brand ... 72% off. , As a leader in the garment industry, ... a good place for ladies who want to purchase charming ...
Breaking Medicine News(10 mins):Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:Fadhits.com Announces a Special Offer on Elegant Quinceanera Dresses 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 2Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 3Health News:Lipitor Lawsuits Move Forward With Scheduling Of First Bellwether Trial 4Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 3Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 4Health News:New Collection of Long Graduation Dresses Revealed by Fadhits.com 2
(Date:7/11/2014)... of kidney injury related to the use of hydroxyethyl ... HES molecules, according to a report in Anesthesia ... Research Society (IARS). , The "total mass of HES ... human renal proximal tubule cells (PTCs), concludes the laboratory ... Hospital Wrzburg, Austria. Other factorssuch as differences in ...
(Date:7/11/2014)... to the hippocampus, the marginal division of the ... What is the impact degree of substance P ... memory function? Yan Yu and his team, College ... using immunofluorescence staining, that substance P receptor, neurokinin ... striatal marginal division of normal rats. Unilateral or ...
(Date:7/11/2014)... Evidence exists that cannabinoid receptor type 1 ... Ca2+ influx, and reduce neurotransmitter release. However, ... 1 can increase extracellular Ca2+ influx and ... his team, Tongji Hospital Affiliated to Tongji ... Technology, China used whole cell voltage-clamp and ...
Breaking Biology News(10 mins):In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
Other Contents